This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kasuya, H. Articles by Tanabe, K. K. Search for Related Content PubMed PubMed Citation Articles by Kasuya, H. Articles by Tanabe, K. K.

Mouse Models of Subcutaneous Spleen Reservoir for Multiple Portal Venous Injections to Treat Liver Malignancies

¹ Division of Surgical Oncology, Massachusetts General Hospital Cancer Center and ² Harvard Medical School, Boston, Massachusetts

Requests for reprints: Kenneth K. Tanabe, Division of Surgical Oncology, Massachusetts General Hospital, Boston, MA 02114. Phone: 617-724-3868; Fax: 617-724-3895; E-mail: KTanabe{at}Partners.org.

Dog and rat animal models have been developed for repeated intravascular administrations to the liver. However, mice have generally been considered too small to use for these models. This study describes the development of mouse models that permit the establishment of liver metastases that can be subsequently treated by repeated injections into the portal venous system. A mini-laparotomy is done to mobilize the spleen and transpose it to a s.c. pocket with its vascular pedicle intact. A suspension of single tumor cells is then inoculated into the portal vein to establish diffuse liver metastases. These tumors may be treated by simple percutaneous injections directly into the s.c. whole spleen reservoir. The ease of injection into the s.c. spleen permits repeated injections into the portal venous system. The usefulness of this model was shown in experiments revealing that multiple portal venous administrations of a replication-conditional, oncolytic herpes simplex virus mutant are more effective than a single portal venous administration. In a modification of this model, the spleen is first split into two, leaving intact the vascular pedicle for each half of the spleen. Tumor cells are inoculated into one hemi-spleen, which is then resected 10 minutes later. The other hemi-spleen is transposed to the s.c. position, thereby permitting subsequent repetitive portal venous injections via percutaneous injections into the s.c. hemi-spleen. These mouse models are useful for a wide range of studies.

This article has been cited by other articles:

				J. E. Hansen, L. K. Fischer, G. Chan, S. S. Chang, S. W. Baldwin, R. J. Aragon, J. J. Carter, M. Lilly, R. N. Nishimura, R. H. Weisbart, et al. Antibody-Mediated p53 Protein Therapy Prevents Liver Metastasis In vivo Cancer Res., February 15, 2007; 67(4): 1769 - 1774. [Abstract] [Full Text] [PDF]